CoChat
Sign Up
Cited by 227

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

Welder, Greg, Zineh, Issam, Pacanowski, Michael A., Troutt, Jason S., Cao, Guoqing, Konrad, Robert J.·2010·Journal of Lipid Research
DOI 10.1194/jlr.m008144
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m008144

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Statin therapy increases hepatic Ldlr and plasma Pcsk9 activity, limiting its effect on LDL-cholesterol.

    “Of note, statin therapy not only increases hepatic Ldlr, but also plasma Pcsk9 activity, thus limiting its effect on LDL-cholesterol.23”

    From The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (2015) · cites this paper as [23]

    The Discussion says statins increase LDLR and PCSK9 gene expression, and reports increased circulating PCSK9 protein after atorvastatin treatment. It proposes that increased PCSK9 may explain the limited additional LDL-C lowering from higher statin doses, but explicitly calls that explanation unproven. The study measures PCSK9 protein levels, not plasma PCSK9 activity. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. Horton, 2007, Molecular biology of PCSK9: its role in LDL metabolism, Trends Biochem. Sci., 32, 71, 10.1016/j.tibs.2006.12.008 · DOI · Paper page
  2. Cao, 2008, Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease, Endocr. Metab. Immune Disord. Drug Targets., 8, 238, 10.2174/187153008786848286 · DOI
  3. Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism, J. Lipid Res., 50, S172, 10.1194/jlr.R800091-JLR200 · DOI · Paper page
  4. Seidah, 2009, PCSK9 as a therapeutic target of dyslipidemia, Expert Opin. Ther. Targets., 13, 19, 10.1517/14728220802600715 · DOI · Paper page
  5. Lambert, 2006, PCSK9: a promising therapeutic target for dyslipidemias, Trends Endocrinol. Metab., 17, 79, 10.1016/j.tem.2006.02.001 · DOI
  6. Mousavi, 2009, The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis, J. Intern. Med., 266, 507, 10.1111/j.1365-2796.2009.02167.x · DOI
  7. Lakoski, 2009, Genetic and metabolic determinants of plasma PCSK9 levels, J. Clin. Endocrinol. Metab., 94, 2537, 10.1210/jc.2009-0141 · DOI · Paper page
  8. McNutt, 2009, Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells, J. Biol. Chem., 284, 10561, 10.1074/jbc.M808802200 · DOI
  9. Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J. Lipid Res., 49, 1303, 10.1194/jlr.M800027-JLR200 · DOI · Paper page
  10. Qian, 2007, Secreted proprotein convertase subtilisin/kexin-type 9 reduces low-density lipoprotein receptor through receptor-mediated endocytosis, J. Lipid Res., 48, 1488, 10.1194/jlr.M700071-JLR200 · DOI · Paper page
  11. Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. USA., 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  12. Graham, 2007, Antisense inhibition of proprotein convertase subtilisin kexin 9 reduces serum LDL in hyperlipidemic mice, J. Lipid Res., 48, 763, 10.1194/jlr.C600025-JLR200 · DOI
  13. Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J. Clin. Invest., 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  14. Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post- endoplasmic reticulum compartment, Proc. Natl. Acad. Sci. USA., 102, 2069, 10.1073/pnas.0409736102 · DOI · Paper page
  15. Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J. Biol. Chem., 279, 50630, 10.1074/jbc.M410077200 · DOI · Paper page
  16. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  17. Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. USA., 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  18. Schmidt, 2008, Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo, Biochem. Biophys. Res. Commun., 370, 634, 10.1016/j.bbrc.2008.04.004 · DOI
  19. Li, 2007, Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity, Biochem. J., 406, 203, 10.1042/BJ20070664 · DOI
  20. McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J. Biol. Chem., 282, 20799, 10.1074/jbc.C700095200 · DOI · Paper page
  21. Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  22. Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proc. Natl. Acad. Sci. USA., 106, 9820, 10.1073/pnas.0903849106 · DOI · Paper page
  23. Maxwell, 2005, Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia, Curr. Opin. Lipidol., 16, 167, 10.1097/01.mol.0000162321.31925.a3 · DOI · Paper page
  24. Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  25. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  26. Allard, 2005, Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum. Mutat., 26, 497, 10.1002/humu.9383 · DOI
  27. Humphries, 2009, Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9, Clin. Chem., 55, 2153, 10.1373/clinchem.2009.129759 · DOI
  28. Fasano, 2007, A novel loss-of-function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol, Arterioscler. Thromb. Vasc. Biol., 27, 677, 10.1161/01.ATV.0000255311.26383.2f · DOI
  29. Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am. J. Hum. Genet., 79, 514, 10.1086/507488 · DOI
  30. Cariou, 2009, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia, Arterioscler. Thromb. Vasc. Biol., 29, 2191, 10.1161/ATVBAHA.109.194191 · DOI
  31. Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. USA., 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  32. Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler. Thromb. Vasc. Biol., 26, 1094, 10.1161/01.ATV.0000204337.81286.1c · DOI · Paper page
  33. Dong, 2010, Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters, J. Lipid Res., 51, 1486, 10.1194/jlr.M003566 · DOI
  34. Alborn, 2007, Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol, Clin. Chem., 53, 1814, 10.1373/clinchem.2007.091280 · DOI
  35. Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J. Lipid Res., 49, 394, 10.1194/jlr.M700437-JLR200 · DOI
  36. Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications, J. Lipid Res., 51, 140, 10.1194/jlr.M900273-JLR200 · DOI
  37. Zineh, 2006, Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study, Pharmacotherapy., 26, 1572, 10.1592/phco.26.11.1572 · DOI
  38. Welder, 2006, Complementary and alternative medicine use among individuals participating in research: implications for research and practice, Pharmacotherapy., 26, 1794, 10.1592/phco.26.12.1794 · DOI
  39. Troutt, 2010, Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels, J. Lipid Res., 51, 345, 10.1194/jlr.M000620 · DOI
  40. Mayne, 2008, Plasma PCSK9 levels are significantly modified by statins and fibrates in humans, Lipids Health Dis., 7, 22, 10.1186/1476-511X-7-22 · DOI
  41. Cariou, 2010, Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients, Atherosclerosis, 10.1016/j.atherosclerosis.2010.04.015 · DOI

Cited by

Sorted by citations

Metadata

Authors
Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2010-09
Volume
51
Issue
9
Pages
2714-2721
ISSN
0022-2275
DOI
10.1194/jlr.m008144
Cited by
227
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review